Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,600

Employees17,600

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,600

Employees17,600

GILD Key Statistics

Market cap

142.10B

Market cap142.10B

Price-Earnings ratio

22.79

Price-Earnings ratio22.79

Dividend yield

2.72%

Dividend yield2.72%

Average volume

6.75M

Average volume6.75M

High today

$117.94

High today$117.94

Low today

$114.18

Low today$114.18

Open price

$117.49

Open price$117.49

Volume

6.47M

Volume6.47M

52 Week high

$121.83

52 Week high$121.83

52 Week low

$81.57

52 Week low$81.57

GILD News

Simply Wall St 2d

Gilead Sciences Commits To Veeva Systems For Vault CRM Suite

recently announced that Gilead Sciences has committed to using its Veeva Vault CRM, highlighting the company's expansion in the pharmaceutical CRM space through...

Simply Wall St 4d

Is Gilead Sciences Undervalued? A Fresh Look at Valuation Without Major Headlines

Advertisement Most Popular Narrative: 6.8% Undervalued Gilead Sciences (GILD) has caught the eye of many investors lately, thanks to some noticeable movement...

TipRanks 6d

Gilead Sciences Advances GS-4321 Study for Chronic Hepatitis Delta

Gilead Sciences ((GILD)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...

Analyst ratings

70%

of 30 ratings

Buy

70%

Hold

30%

Sell

More GILD News

TipRanks 6d

Gilead Sciences Advances Pediatric HIV Treatment with New Study Update

Gilead Sciences ((GILD)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...

TipRanks 6d

Gilead Sciences Advances Endometrial Cancer Treatment with New Phase 3 Study

Gilead Sciences ((GILD)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...

TipRanks 6d

Gilead’s Lenacapavir: A Game-Changer in HIV Prevention?

Gilead Sciences ((GILD)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Un...

TipRanks 6d

Gilead Sciences’ Promising Phase 3 Study in Triple Negative Breast Cancer

Gilead Sciences ((GILD)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Un...

TipRanks 6d

Gilead Sciences Launches New Study on GS-5319 for Advanced Solid Tumors

Gilead Sciences ((GILD)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

VeriSign

Exelixis

United Therapeutics

Sprouts Farmers Market

Spotify

Franco-Nevada